Filing Details

Accession Number:
0000899243-20-020687
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-29 21:38:37
Reporting Period:
2020-07-28
Accepted Time:
2020-07-29 21:38:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1808865 Iteos Therapeutics Inc. ITOS () 1231
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1015747 Joseph Lewis 11682 El Camino Real, Suite 320
San Diego CA 92130
No No Yes No
1465836 Boxer Asset Management Inc. 11682 El Camino Real, Suite 320
San Diego CA 92130
No No Yes No
1465837 Boxer Capital, Llc 11682 El Camino Real, Suite 320
San Diego CA 92130
No No Yes No
1468223 Mva Investors, Llc 11682 El Camino Real, Suite 320
San Diego CA 92130
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-28 2,943,568 $0.00 2,943,568 No 4 C Direct
Common Stock Acquisiton 2020-07-28 48,691 $0.00 48,691 No 4 C Direct
Common Stock Acquisiton 2020-07-28 1,401,448 $19.00 4,345,016 No 4 P Direct
Common Stock Acquisiton 2020-07-28 23,552 $19.00 72,243 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B-2 Preferred Stock Disposition 2020-07-28 9,593,086 $0.00 2,943,568 $0.00
Common Stock Series B-2 Preferred Stock Disposition 2020-07-28 158,687 $0.00 48,691 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
  2. The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
  3. These securities are owned directly by Boxer Capital, which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
  4. These securities are owned directly by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
  5. On July 28, 2020, Boxer Capital purchased 1,401,448 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
  6. On July 28, 2020, MVA Investors purchased 23,552 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.